IN8BIO INC. - COMMON STOCK

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

24 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

14 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

11 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

IN8bio to Present at Biotech Showcase 2025 in San Francisco

06 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

10 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

02 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting

25 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

12 Nov 2024 15:26:01 By Nasdaq GlobeNewswire

IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

12 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting

05 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

IN8bio Announces Pricing of $12.4 Million Private Placement

01 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

04 Sep 2024 15:01:00 By Nasdaq GlobeNewswire

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

29 Aug 2024 05:05:00 By Nasdaq GlobeNewswire

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

12 Aug 2024 07:05:00 By Nasdaq GlobeNewswire

IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

08 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

24 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

13 Jun 2024 15:01:00 By Nasdaq GlobeNewswire

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

03 Jun 2024 05:05:00 By Nasdaq GlobeNewswire

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

24 May 2024 07:00:00 By Nasdaq GlobeNewswire

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

23 May 2024 16:00:00 By Nasdaq GlobeNewswire